Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

[1]  Yusuke Nakamura,et al.  Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study , 2016, Cancer science.

[2]  H. Nagano,et al.  Prediction of the efficacy of immunotherapy by measuring the integrity of cell‐free DNA in plasma in colorectal cancer , 2016, Cancer science.

[3]  J. Rosenblatt,et al.  Myeloid‐derived suppressor cells as effectors of immune suppression in cancer , 2016, International journal of cancer.

[4]  T. Pawlik,et al.  Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  M. Yao,et al.  Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy , 2016, BioMed Research International.

[6]  Shiguang Zhu,et al.  Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. , 2016, Immunobiology.

[7]  H. Nishikawa,et al.  Roles of regulatory T cells in cancer immunity. , 2016, International immunology.

[8]  H. Lee,et al.  Systemic Chemotherapy in Advanced Pancreatic Cancer , 2016, Gut and liver.

[9]  H. Nagano,et al.  Combined adjuvants of poly(I:C) plus LAG‐3‐Ig improve antitumor effects of tumor‐specific T cells, preventing their exhaustion , 2016, Cancer science.

[10]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[11]  H. Saito,et al.  An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer , 2016, Surgery Today.

[12]  T. Todros,et al.  Amniotic mesenchymal cells from pre‐eclamptic placentae maintain immunomodulatory features as healthy controls , 2015, Journal of cellular and molecular medicine.

[13]  D. V. Von Hoff,et al.  Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). , 2016, European journal of cancer.

[14]  I. Mercier,et al.  Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators , 2015, Front. Immunol..

[15]  A. Thiel,et al.  Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression , 2015, Cancer Immunology, Immunotherapy.

[16]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[17]  W. Fang,et al.  Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer , 2015, Oncotarget.

[18]  Yusuke Nakamura,et al.  A clinical trial of multiple peptides vaccination for advanced head and neck cancer patients induced immune responses and prolonged OS , 2015, Oncoimmunology.

[19]  M. Oka,et al.  Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. , 2015, Anticancer research.

[20]  Yusuke Nakamura,et al.  Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. , 2014, Anticancer research.

[21]  M. Oka,et al.  Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer , 2014, Journal of Translational Medicine.

[22]  Peng-jun Zhang,et al.  Development of serum parameters panels for the early detection of pancreatic cancer , 2014, International journal of cancer.

[23]  Yusuke Nakamura,et al.  A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) , 2014, Journal of Translational Medicine.

[24]  Yusuke Nakamura,et al.  A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome , 2014, Journal of Translational Medicine.

[25]  Shigemi Matsumoto,et al.  Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients , 2014, Cancer medicine.

[26]  K. Hirakawa,et al.  A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer. , 2013, Anticancer research.

[27]  A. Sarnaik,et al.  Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma , 2013, Cancer Immunology, Immunotherapy.

[28]  T. Whiteside.  Immune Responses to Cancer: Are They Potential Biomarkers of Prognosis? , 2013, Front. Oncol..

[29]  Yusuke Nakamura,et al.  Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens , 2012, Journal of Translational Medicine.

[30]  S. Kitano,et al.  Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens , 2012, Journal of Translational Medicine.

[31]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[32]  Yusuke Nakamura,et al.  Recent advances in active specific cancer vaccine treatment for colorectal cancer. , 2012, Current pharmaceutical biotechnology.

[33]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[34]  A. Dalgleish,et al.  Biomarkers for the Development of Cancer Vaccines , 2006, Molecular Diagnosis & Therapy.

[35]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  K. Okuno,et al.  Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. , 2010, Experimental and therapeutic medicine.

[37]  S. Sakaguchi,et al.  Regulatory T cells in tumor immunity , 2010, International journal of cancer.

[38]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[39]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Shibuya,et al.  Inhibition of Tumor Growth with Antiangiogenic Cancer Vaccine Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 1 , 2006, Clinical Cancer Research.

[41]  M. Shibuya,et al.  Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. , 2005, Cancer research.

[42]  K. Taniuchi,et al.  Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. , 2005, Cancer research.

[43]  Yusuke Nakamura,et al.  Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. , 2005, Cancer research.

[44]  T. Tsunoda,et al.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. , 2001, Cancer research.

[45]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[48]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.